Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close

, MT Newswires - 3:25 PM ET 3/21/2025 default

03:25 PM EDT, 03/21/2025 (MT Newswires) -- Adaptive Biotechnologies ( ADPT ) still was trading more than 6% higher late in Friday's session, roughly halving its earlier advance after analysts at Goldman Sach raised their stock rating for the immuno-sequencing company to buy from neutral previously.

The Goldman analysts also increased their price target for Adaptive shares to $9 from their prior call of $8 per share.

Price: 8.24, Change: +0.48, Percent Change: +6.26

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.